3 completed, 2 active not recruiting, 1 terminated. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 2, Terminated 1 |
Follow EpicentRx, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2 - Oral Mucositis | Phase 2 | Active not recruiting | EpicentRx, Inc. | 216 | 2024-04-02 | 2026-06-26 |
| A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors AdAPT-001, Checkpoint Inhibitor, Immune - Solid Tumor, Adult, Cancer | Phase 2 | Active not recruiting | EpicentRx, Inc. | 140 | 2021-03-29 | 2026-06-26 |
| Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers RRx-001, Cisplatin for injection, Radiation Therapy - Oral Mucositis | Phase 2 | Completed | EpicentRx, Inc. | 53 | 2018-07-12 | 2024-11-04 |
| RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy RRx-001, Gemcitabine and cisplatin - Cholangiocarcinoma | Phase 2 | Terminated | EpicentRx, Inc. | 4 | 2015-07-16 | 2024-04-24 |
| RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) RRx-001, Cisplatin, Etoposide - Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | EpicentRx, Inc. | 139 | 2015-06-01 | 2025-03-17 |
| A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer RRx-001, Regorafenib, Irinotecan - Colorectal Neoplasms | Phase 2 | Completed | EpicentRx, Inc. | 62 | 2014-05-01 | 2024-10-15 |
Head and Neck Neoplasms (2) · Mouth Neoplasms (2) · Mucositis (2) · Stomatitis (2) · Adenoviridae Infections (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Small Cell (1) · Carcinoma, Squamous Cell (1) · Cholangiocarcinoma (1) · Chondrosarcoma (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1) · Neuroendocrine Tumors (1)
RRx-001 (5) · Cisplatin (4) · Gemcitabine (2) · Injections (2) · Irinotecan (2) · 130-nm albumin-bound paclitaxel (1) · Bevacizumab (1) · Carboplatin (1) · Etoposide (1) · Immune Checkpoint Inhibitors (1) · Paclitaxel (1) · Pemetrexed (1) · Radiotherapy (1) · Radiotherapy, Intensity-Modulated (1) · Vinorelbine (1)
United States (6)
Bryan Oronsky, MD, PhD (2) · Ana De Jesus Acosta, MD (1) · Bryan Oronsky, MD (1) · Bryan Oronsky, MD PhD (1) · Meaghan Stirn (1)
PMID 24575021, PMID 31231122, PMID 33569311, PMID 35950603, PMID 36529613, PMID 39461878